Dohi Y, Iki M, Ohgushi H, Gojo S, Tabata S, Kajita E, Nishino H, Yonemasu K
Department of Public Health, Nara Medical University, Kashihara, Japan.
J Bone Miner Res. 1998 Oct;13(10):1633-9. doi: 10.1359/jbmr.1998.13.10.1633.
We present a polymorphism of the human osteocalcin gene (also known as BGP, for bone Gla protein) due to a 1 base pair (bp) substitution from cytosine to thymine at position 298 nucleotides (nt), which is at position 198 nt upstream from the BGP exon 1. This mutation was detected by single-strand conformation polymorphism analysis after polymerase chain reaction for the osteocalcin gene fragment (326 bp) and sequencing analysis. The cytosine/thymine polymorphism can be defined by restriction fragment length polymorphism analysis using a modified primer pair and the restriction endonuclease HindIII. The osteocalcin genotype was determined in 160 postmenopausal Japanese women (age 48-80 years). Osteocalcin alleles were designated according to the absence (H) or presence (h) of the HindIII restriction site. There were 12 HH, 49 Hh, and 99 hh individuals, and the allele frequencies were 22.8% for H and 77.2% for h. To determine if genetic variation influences bone mineral density (BMD) and thus can be a determinant of susceptibility to osteoporosis in older women, we examined the association of BMD with the osteocalcin genotypes found in the present study. The subjects with genotype HH had the smallest BMD and those with hh had the greatest BMD among subjects, but these differences did not reach statistical significance. The HindIII genotype showed a significant effect on the prevalence of osteopenia in the subjects, that is, women with genotype HH had a 5.74 times greater risk for osteopenia (p < 0.05) and those with genotype Hh had a 1.59 times greater risk than women with genotype hh. We identified the osteocalcin gene polymorphism, detected with the HindIII genotype, which was suggested to influence bone density and is a possible genetic marker for bone metabolism.
我们报告了人类骨钙素基因(也称为BGP,即骨钙蛋白)的一种多态性,它是由于第298个核苷酸(nt)处的1个碱基对(bp)由胞嘧啶替换为胸腺嘧啶所致,该位置位于BGP外显子1上游198 nt处。通过对骨钙素基因片段(326 bp)进行聚合酶链反应后的单链构象多态性分析和测序分析检测到了这种突变。胞嘧啶/胸腺嘧啶多态性可以通过使用修饰的引物对和限制性内切酶HindIII进行限制性片段长度多态性分析来确定。在160名绝经后日本女性(年龄48 - 80岁)中确定了骨钙素基因型。根据HindIII限制性位点的有无将骨钙素等位基因命名为(H)或(h)。有12名HH个体、49名Hh个体和99名hh个体,等位基因频率分别为H:22.8%,h:77.2%。为了确定基因变异是否会影响骨矿物质密度(BMD),从而成为老年女性骨质疏松易感性的一个决定因素,我们研究了本研究中发现的骨钙素基因型与BMD之间的关联。在研究对象中,基因型为HH的个体BMD最小,hh个体的BMD最大,但这些差异未达到统计学显著性。HindIII基因型对研究对象中骨质减少的患病率有显著影响,即基因型为HH的女性患骨质减少的风险比基因型为hh的女性高5.74倍(p < 0.05),基因型为Hh的女性患骨质减少的风险比基因型为hh的女性高1.59倍。我们鉴定了通过HindIII基因型检测到的骨钙素基因多态性,它被认为会影响骨密度,并且是骨代谢的一个可能的遗传标记。